-
Sep. 10, 2020
Gemini Therapeutics Enrolls First Patient in Phase 2a Study of GEM103 for Dry Age-related Macular Degeneration
CAMBRIDGE, Mass. —(BUSINESS WIRE)— Gemini Therapeutics, a clinical stage precision medicine company developing innovative treatments for genetically defined Age-related Macular Degeneration (AMD) and linked ocular disorders, today announced the initiation of enrollment in its Phase 2a “ReGAtta” study.
-
Aug. 27, 2020
Gemini Therapeutics Appoints Dr. Tuyen Ong as Independent Director
Ophthalmology innovator brings more than 20 years of clinical and drug development experience to the Board of Directors. CAMBRIDGE, Mass. —(BUSINESS WIRE)— Gemini Therapeutics, a clinical stage precision medicine company developing innovative treatments for genetically defined Age-related Macular Degeneration (AMD) and linked ocular disorders, today announced that Dr. Tuyen Ong has been appointed to serve …
-
May. 7, 2020
Gemini Therapeutics Appoints Marc E. Uknis, MD, FACS as Chief Medical Officer
CAMBRIDGE, Mass. – May 7, 2020 – Gemini Therapeutics, a clinical stage precision medicine company developing innovative treatments for dry Age-related Macular Degeneration (AMD) and linked ocular disorders, today announced that Marc E. Uknis MD, FACS has been appointed to serve as Chief Medical Officer, effective today. Dr. Uknis brings more than 35 years of …
-
Apr. 28, 2020
Gemini Therapeutics Appoints David Lubner as Independent Director
CAMBRIDGE, Mass. – Gemini Therapeutics, a clinical stage precision medicine company developing innovative treatments for dry Age-related Macular Degeneration (AMD) and linked ocular disorders, today announced that David Lubner has been appointed to serve as an independent member of its Board of Directors. “David is an accomplished finance executive, with more than 20 years of …
-
Feb. 26, 2020
Gemini Therapeutics and Singapore Eye Research Institute Enter Into Research Collaboration to Explore New Targets for Age-related Macular Degeneration
CAMBRIDGE, Mass.—(BUSINESS WIRE)—Gemini Therapeutics, a clinical stage precision medicine company developing innovative treatments for dry Age-related Macular Degeneration (AMD) and linked ocular disorders, today announced a collaboration with the Singapore Eye Research Institute (SERI) to expand knowledge and identify new targets associated with AMD. Under the terms of the agreement, SERI and Gemini will explore …
-
Jan. 9, 2020
Gemini Therapeutics Enrolls First Patient in Phase 1 Study of GEM103 for Dry Age-related Macular Degeneration
Study is enrolling patients with high-risk genetic variants for dry AMD, a common cause of blindness. Potential to initiate a Phase 2 study supported by the CLARITY natural history study data. Gemini Therapeutics, a clinical stage precision medicine company developing innovative treatments for dry age-related macular degeneration (AMD) and linked ocular disorders, today announced it …
-
Sep. 13, 2019
Gemini Therapeutics Announces Leadership Appointment
Jason Meyenburg Joins Gemini Therapeutics as CEO Cambridge, Mass., September 13, 2019 – Gemini Therapeutics, a precision medicine company developing innovative treatments for age-related macular degeneration (AMD) and linked ocular disorders, today announced the appointment of Jason Meyenburg, MBA, as Chief Executive Officer (CEO). Mr. Meyenburg will also join the company’s Board of Directors. “We are thrilled …
-
Jan. 7, 2019
Gemini Therapeutics Announces the Initiation of CLARITY, a Disease Registry and Natural History Study of Subjects with Dry AMD and High-Risk Genotypes
Gemini initiates the largest and most complete longitudinal prospective clinical study to date of subjects with dry Age-Related Macular Degeneration (AMD) who are carriers of high-risk genotypes Cambridge, Mass., January 7, 2019 – Gemini Therapeutics, a product engine company focused on redefining dry AMD and linked disorders with precision medicine, today announced the initiation of CLARITY, a …
-
Nov. 27, 2018
Gemini Therapeutics Announces Presentation at the Piper Jaffray 30th Annual Healthcare Conference
Cambridge, Mass., November 27, 2018 – Gemini Therapeutics today announced that Chief Executive Officer James McLaughlin will present a company overview at the Piper Jaffray 30th Annual Healthcare Conference in New York, NY. The presentation will take place on Tuesday, November 27, 2018 at 8:30 a.m. ET. Gemini Therapeutics Gemini Therapeutics is a product engine company using the process …
-
Oct. 25, 2018
Gemini Therapeutics Announces Presentation at the Ophthalmology Innovation Summit at the 2018 Annual Meeting of the American Academy of Ophthalmology (OIS@AAO)
Cambridge, Mass., October 25, 2018 – Gemini Therapeutics, , today announced that Chief Executive Officer James McLaughlin will provide a company overview at the 2018 Ophthalmology Innovation Summit at the Annual Meeting of the American Academy of Ophthalmology (OIS@AAO). James McLaughlin will present during the “Company Showcase” session, to be held from 9:05 – 10:05 a.m. …
